- $94.97m
- $65.85m
- 29
- 54
- 59
- 44
Annual income statement for Instil Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.138 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 33.8 | 156 | 226 | 159 | 73.5 |
| Operating Profit | -33.6 | -156 | -226 | -159 | -73.5 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -37.6 | -157 | -225 | -156 | -74.1 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -37.7 | -157 | -223 | -156 | -74.1 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -37.7 | -157 | -223 | -156 | -74.1 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -37.7 | -157 | -223 | -156 | -74.1 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -6 | -29.6 | -32.1 | -12.9 | -8.7 |
| Dividends per Share |